Therapeutic Asset Ratings

193 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
(+)-VINCRISTINE Endometrial Cancer	Whitehawk Therapeutics, Inc.	P2	B (56)
FLUTICASONE Endometrial Cancer	Mayo Clinic	P2	CCC (55)
Metformin Endometrial Cancer	Dana-Farber Cancer Institute	P2	CCC (55)
Sargramostim Endometrial Cancer	Mayo Clinic	P2	CCC (55)
Medroxyprogesterone acetate Endometrial Cancer	Peking University People's Hospital	P3	CCC (54)
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- Endometrial Cancer	Sichuan Cancer Hospital and Research Institute	P3	CCC (54)
Durvalumab Endometrial Cancer	Vall d'Hebron Institute of Oncology	P2	CCC (54)
Ipilimumab Endometrial Cancer	National Cancer Institute (NCI)	P2	CCC (54)
Loperamide Endometrial Cancer	National Cancer Institute (NCI)	P2	CCC (54)
Nivolumab Endometrial Cancer	Parabilis Medicines, Inc.	P2	CCC (54)
MEGESTROL ACETATE IMPURITY B Endometrial Cancer	Peking University People's Hospital	P2/3	CCC (54)
Cediranib Endometrial Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Alpelisib Endometrial Cancer	National Cancer Institute (NCI)	P2	CCC (52)
Arimidex Endometrial Cancer	Jonsson Comprehensive Cancer Center	P2	CCC (52)
Bendamustine Endometrial Cancer	M.D. Anderson Cancer Center	P2	CCC (52)
Canagliflozin Endometrial Cancer	Faeth Therapeutics	P2	CCC (52)
Capecitabine Endometrial Cancer	AstraZeneca	P2	CCC (52)
Datopotamab Deruxtecan Endometrial Cancer	AstraZeneca	P2	CCC (52)
Everolimus Endometrial Cancer	Eli Lilly and Company	P2	CCC (52)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER Endometrial Cancer	Eli Lilly and Company	P2	CCC (52)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER Endometrial Cancer	M.D. Anderson Cancer Center	P2	CCC (52)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Endometrial Cancer	Vall d'Hebron Institute of Oncology	P2	CCC (52)
Relatlimab Endometrial Cancer	Regeneron Pharmaceuticals	P2	CCC (52)
Tirzepatide Endometrial Cancer	UNC Lineberger Comprehensive Cancer Center	P2	CCC (52)
Tpst-1495 Endometrial Cancer	University of Oklahoma	P2	CCC (52)

Showing 26 to 50 of 193 assets

PreviousPage 2 of 8Next